Roles in PharmNovo: Business advisor and Director of the board.
Education: Ph.D. Trained in neuropharmacology and holds a Ph.D. from the University of Nottingham (UK).
Work experience: Co-founded Afferent Pharmaceuticals, Inc. in 2009 and served as its Chief Scientific Officer until it’s take over by Merck in 2016. Dr. Ford has more than 20 years of research and development experience at Roche (where he served as Vice President) Syntex and Afferent, having led the progression of several novel drug candidates into early clinical development, focused particularly in the areas of pain and genitourinary therapeutics. He was also responsible for the development of AF-219, a selective P2X3 antagonist for the treatment of pathologic cough.
Roles in PharmNovo: Business and Chemistry advisor and Director of the board.
Education: University of Gothenburg, PhD in organic chemistry.
Work experience: At AZ: Head of Biology department, Project Management, President of Astra Research Center Boston, Vice President Group Internal Control. Different management positions at AstraZeneca, 1978–2006. Chairman of the Board, Kanozi Architects 2008.
Roles in PharmNovo: Business advisor, VP Business development and Director of the board.
Education: Bachelor’s degree in International Business Administration from the University of Lund.
Work experience: 30 years of experience from International business in various industries and has vast experience in developing and transforming mid-size businesses. In 2003–2007 Per was VP Marketing & Sales for Nybron Flooring, European market leader in parquet flooring, with HQ in Switzerland and during 2008–2017 he was CEO at Elfa International with HQ in Malmö, Sweden.
Roles in PharmNovo: Business and scientific advisor.
Education: Medical education from Copenhagen University from 1981. 6 years of hospital service within surgery, anesthesiology and internal medicine.
Work experience: Peder has more than 25 years of experience from large pharma, medium pharma and small/virtual biotech pharma. He has worked within oncology, diabetes, neurology, dermatology and was in his earlier days as consultant involved in testing cannabinol for neuropathic pain. He has established his own company and sold it to larger pharma. He has held senior positions in Orion Pharma, Novo Nordisk, Astion Pharma and Forward Pharma. He has held numerous meetings with both FDA, EMA, European agencies as well as Australian and New Zealand authorities. With Forward Pharma he was as CEO/COO heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq October 2014 (raised 235M USD). Forward Pharma did also complete a license deal with Biogen Idec with a down payment of 1.25B USD. He holds currently the position as CEO at Biosergen AS, Norway.